Orange skin and xanthomas associated with lycopenaemia in a setting of type III dyslipoproteinaemia;Coloration orangée des téguments et des xanthomes au cours d'une lycopénémie associée à une dyslipoprotéinémie de type III

Annales de Dermatologie et de Venereologie

Volumn 136, Issue 1, 2009, Pages 42-45

  Royer, M ^a   Bulai Livideanu, C ^a   Periquet, B ^b   Maybon, P ^c   Lamant, L ^d   Mazereeuw Hautier, J ^a   Ferrieres J ^b   Paul, C ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b CHU RANGUEIL   (France)

^c Cabinet de dermatologie   (France)

^d CHU PURPAN   (France)

Author keywords

Carotenoids; Dyschromia; Hyperlipoproteinaemia; Lycopenaemia; Orange skin

Indexed keywords

CANDESARTAN; CANDESARTAN HEXETIL; EZETIMIBE; LEVOTHYROXINE; LIPID; LYCOPENE; NICOTINIC ACID; THYROXINE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIETARY INTAKE; DISEASE ASSOCIATION; DYSLIPOPROTEINEMIA; DYSLIPOPROTEINEMIA TYPE III; FEMALE; HISTOPATHOLOGY; HUMAN; LIPID BLOOD LEVEL; PALMAR CREASE XANTHOMA; PEAU D'ORANGE; SKIN DISCOLORATION; SKIN DISEASE; TUBEROUS XANTHOMA; VITAMIN BLOOD LEVEL; XANTHOMA;

ANTILIPEMIC AGENTS; AZETIDINES; CAROTENOIDS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; MIDDLE AGED; NIACIN; PIGMENTATION DISORDERS; SKIN DISEASES; XANTHOMATOSIS;

EID: 61549112143     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2008.07.062     Document Type: Article

References (14)

1. La Placa M., Pazzaglia M., and Tosti A. Lycopenaemia. J Eur Acad Dermatol Venereol 14 (2000) 311-312
2. Reich P., Shwachman H., and Craig J.M. Lycopenemia: a variant of carotenemia. N Engl J Med 262 (1960) 263-269
3. Bonnetblanc J.M., Bonafe J.L., and Vidal E. Caroténodermies diététiques. Ann Dermatol Venereol 114 (1987) 1093-1096
4. Aloy M., Pantin M., and Torres Peris V. Clinical features of carotenemia. Med Cutan Ibero Lat Am 13 (1985) 31-34
5. Walfisch Y., Walfisch S., Agbaria R., Levy J., and Sharoni Y. Lycopene in serum, skin and adipose tissues after tomato-oleoresin supplementation in patients undergoing haemorrhoidectomy or perianal fistulotomy. Br J Nutr 90 (2003) 759-766
6. Mahley R.W., Huang Y., and Rall S.C. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries and paradoxes. J Lipid Res 40 (1999) 1933-1949
7. Farnier M., Bonnet F., Bruckert E., Ferrières J., and Paillard F. Quand proposer une association d'hypolipémiants chez un patient non à l'objectif thérapeutique sous monothérapie ? Recommandations de la Nouvelle Société française d'athérosclérose. Arch Mal Cœur Vaiss 100 (2007) 569-581
8. Vogel S., Contois J.H., Tucker K.L., Wilson P.W., Schaefer E.J., and Lammi-Keefe C.J. Plasma retinol and plasma and lipoprotein tocopherol and carotenoid concentrations in healthy elderly participants of the Framingham Heart Study. Am J Clin Nutr 66 (1997) 950-958
9. Demacker P.M., Hectors M.P., and Stalenhoef A.F. Chylomicron processing in familial dysbetalipoproteinemia and familial combined hyperlipidemia studied with vitamin A ant E as markers: a new physiological concept. Atherosclerosis 149 (2000) 169-180
10. Ortega H., Castilla P., Gomez-Coronado D., Garcés C., Benavente M., Rodriguez-Artalejo F., et al. Influence of apolipoprotein E genotype on fat-soluble plasma antioxidants in Spanish children. Am J Clin Nutr 81 (2005) 624-632
11. Brümmer D., Evans D., Berg D., Greten H., Beisiegel U., and Mann W.A. Expression of type III hyperlipoproteinemia in patients homozygous for apolipoprotein E-2 is modulated by lipoprotein lipase and postprandial hyperinsulinemia. J Mol Med 76 (1998) 355-364
12. Hsu Y.M., Lai C.H., Chang C.Y., Fan C.T., Chen C.T., and Wu C.H. Characterizing the lipid-lowering effects and antioxidant mechanisms of tomato paste. Biosci Biotechnol Biochem 72 (2008) 677-685
13. Rissanen T.H., Voutilainen S., Nyyssonen K., and Salonen J.T. Lycopene, atherosclerosis and coronary heart disease. Exp Biol Med 227 (2002) 900-907
14. Rissanen T.H., Voutilainen S., Nyyssönen K., Lakka T.A., Sivenius J., Salonen R., et al. Low serum lycopene concentration is associated with an excess incidence of acute coronary events and stroke: the Kuopio ischaemic heart disease risk factor study. Br J Nutr 85 (2001) 749-754